Clinical characteristics and risk factors of patients with COVID-19 developing barotrauma
Journal of Population Therapeutics and Clinical Pharmacology
; 30(9):e178-e186, 2023.
Artigo
em Inglês
| EMBASE | ID: covidwho-20233238
ABSTRACT
Background:
At our hospital, people with COVID-19 (coronavirus disease 2019) had a high rate of pulmonary barotrauma. Therefore, the current study looked at barotrauma in COVID-19 patients getting invasive and non-invasive positive pressure ventilation to assess its prevalence, clinical results, and features.Methodology:
Our retrospective cohort study comprised of adult COVID-19 pneumonia patients who visited our tertiary care hospital between April 2020 and September 2021 and developed barotrauma. Result(s) Sixty-eight patients were included in this study. Subcutaneous emphysema was the most frequent type of barotrauma, reported at 67.6%;pneumomediastinum, reported at 61.8%;pneumothorax, reported at 47.1%. The most frequent device associated with barotrauma was CPAP (51.5%). Among the 68 patients, 27.9% were discharged without supplemental oxygen, while 4.4% were discharged on oxygen. 76.5% of the patients expired because of COVID pneumonia and its complications. In addition, 38.2% of the patients required invasive mechanical breathing, and 77.9% of the patients were admitted to the ICU. Conclusion(s) Barotrauma in COVID-19 can pose a serious risk factor leading to mortality. Also, using CPAP was linked to a higher risk of barotrauma.Copyright © 2021 Muslim OT et al.
Barotrauma; BiPAP; covid-19; cpap; niv; pneumothorax; adult; arterial pH; article; barotrauma/co [Complication]; bilevel positive airway pressure; blood carbon dioxide tension; blood oxygen tension; clinical feature; clinical outcome; cohort analysis; continuous positive airway pressure; COVID-19 pneumonia/dt [Drug Therapy]; female; fraction of inspired oxygen; high flow nasal cannula therapy; hospital discharge; human; intensive care unit; invasive positive pressure ventilation; male; middle aged; mortality; nasopharyngeal swab; neutrophil lymphocyte ratio; noninvasive positive pressure ventilation; oxygen therapy; pneumomediastinum/co [Complication]; pneumothorax/co [Complication]; polymerase chain reaction; positive end expiratory pressure ventilation; prevalence; retrospective study; risk factor; subcutaneous emphysema/co [Complication]; synchronized intermittent mandatory ventilation; tertiary care center; tidal volume; alanine aminotransferase/ec [Endogenous Compound]; aspartate aminotransferase/ec [Endogenous Compound]; bicarbonate/ec [Endogenous Compound]; brain natriuretic peptide/ec [Endogenous Compound]; C reactive protein/ec [Endogenous Compound]; creatinine/ec [Endogenous Compound]; D dimer/ec [Endogenous Compound]; dexamethasone/dt [Drug Therapy]; ferritin/ec [Endogenous Compound]; gamma glutamyltransferase/ec [Endogenous Compound]; hemoglobin/ec [Endogenous Compound]; lactate dehydrogenase/ec [Endogenous Compound]; low molecular weight heparin/dt [Drug Therapy]; methylprednisolone/dt [Drug Therapy]; methylprednisolone/iv [Intravenous Drug Administration]; procalcitonin/ec [Endogenous Compound]; remdesivir/dt [Drug Therapy]; tocilizumab/dt [Drug Therapy]; urea/ec [Endogenous Compound]; BiPAP device; CPAP device; non rebreathing valve; ventilator
Texto completo:
Disponível
Coleções:
Bases de dados de organismos internacionais
Base de dados:
EMBASE
Tipo de estudo:
Estudo de coorte
/
Estudo observacional
/
Estudo prognóstico
Idioma:
Inglês
Revista:
Journal of Population Therapeutics and Clinical Pharmacology
Ano de publicação:
2023
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS